AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36414993 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed menstrual tracking data
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Black participants
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Class 1 obesity (BMI 30-34.9)
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Class 2 obesity (BMI 35-39.9)
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Class 3 obesity (BMI >40)
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Class 3 obesity
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Polycystic ovary syndrome
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Hyperthyroidism
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Hypothyroidism
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Endometriosis
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Cervical dysplasia
Number of subjects: 18875
Study 36414993 — intervention group
Group type: COMPARATOR
Intervention: Fibroids
Number of subjects: 18875
Study 36415000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Number of subjects: 354
Study 36415000 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 354
Study 36415178 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided laser ablation (EUS-LA)
Number of subjects: 20
Study 36415604 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses of SARS-CoV-2 vaccine (vaccine group)
Number of subjects: 914
Study 36415604 — intervention group
Group type: COMPARATOR
Intervention: Three doses of SARS-CoV-2 vaccine (control group)
Number of subjects: 914
Study 36415604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid immunity (three vaccine doses followed by COVID-19)
Number of subjects: 914
Study 36415604 — intervention group
Group type: EXPERIMENTAL
Intervention: Three and four doses of SARS-CoV-2 vaccine (both groups)
Number of subjects: 914
Study 36415883 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36416136 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (PCSK9i)
Number of subjects: 696
Study 36416787 — intervention group
Group type: EXPERIMENTAL
Intervention: Early KRT initiation
Number of subjects: 4880
Study 36416805 — intervention group
Group type: EXPERIMENTAL
Intervention: 5G-based remote MCE
Number of subjects: 20
Study 36416805 — intervention group
Group type: COMPARATOR
Intervention: Conventional MCE
Number of subjects: 20
Study 36416874 — intervention group
Group type: EXPERIMENTAL
Intervention: CART19/20 cells (36 × 10^6 to 165 × 10^6 cells)
Number of subjects: 10
Study 36416880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-specific meditation app prototype used daily (≥70 minutes per week) for 4 weeks
Number of subjects: 36
Study 36416880 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional web-based poststudy interview
Number of subjects: 36
Study 36416880 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly and poststudy questionnaires
Number of subjects: 36
Study 36417356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 42
Study 36417356 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy x-ray absorptiometry (DXA)
Number of subjects: 42
Study 36417367 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 109
Study 36417367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 36417675 — intervention group
Group type: EXPERIMENTAL
Intervention: epithelium-off accelerated corneal cross-linking (CXL, 9 mW/cm2, 10 min, 5.4 J/cm2)
Number of subjects: 41
Study 36417764 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-diameter bone-anchored hearing implant (loaded at 3 weeks after surgery)
Number of subjects: 51
Study 36417764 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-diameter bone-anchored hearing implant (loaded at 6 weeks after surgery)
Number of subjects: 51
Study 36417764 — intervention group
Group type: COMPARATOR
Intervention: Previous-generation small-diameter bone-anchored hearing implant (loaded at 6 weeks after surgery)
Number of subjects: 51
Study 36417764 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-diameter bone-anchored hearing implant
Number of subjects: 51
Study 36418119 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (protocol-specified antidepressants)
Number of subjects: 200
Study 36418119 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 200
Study 36418122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired pressure injuries (PIs)
Number of subjects: 1312
Study 36418122 — intervention group
Group type: EXPERIMENTAL
Intervention: Braden score and prior length of ICU stay
Number of subjects: 1312
Study 36418127 — intervention group
Group type: EXPERIMENTAL
Intervention: Face mask sampling with polyvinyl alcohol test strips for 2 hours daily over at least 7 days.
Number of subjects: 0
Study 36418127 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered nasal swabs and optional finger prick blood samples.
Number of subjects: 0
Study 36418170 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36418515 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 157
Study 36418966 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR ≥ 8.0 ng/mL in patients with infection
Number of subjects: 871
Study 36418966 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR ≥ 8.0 ng/mL in patients without infection
Number of subjects: 871
Study 36418966 — intervention group
Group type: EXPERIMENTAL
Intervention: Inability to answer questions relating to pain in patients who developed sepsis
Number of subjects: 871
Study 36418966 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR ≥ 8.0 ng/mL in patients who developed sepsis
Number of subjects: 871
Study 36418966 — intervention group
Group type: EXPERIMENTAL
Intervention: Inability to answer questions relating to specific symptoms in patients with infection
Number of subjects: 871
Study 36418965 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (various classes including penicillins, fluoroquinolones, and macrolides)
Number of subjects: 9886
Study 36418965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid and levofloxacin
Number of subjects: 9886
Study 36418965 — intervention group
Group type: EXPERIMENTAL
Intervention: History of cardiac ischemia
Number of subjects: 9886
Study 36418965 — intervention group
Group type: EXPERIMENTAL
Intervention: History of asthma
Number of subjects: 9886
Study 36418965 — intervention group
Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 9886
Study 36418965 — intervention group
Group type: EXPERIMENTAL
Intervention: History of COPD
Number of subjects: 9886
Study 36418965 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 9886
Study 36419331 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-based prophylaxis
Number of subjects: 1288
Study 36419331 — intervention group
Group type: COMPARATOR
Intervention: Empirical prophylaxis with oral ciprofloxacin (control group)
Number of subjects: 1288
Study 36419530 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day gabapentin
Number of subjects: 42
Study 36419530 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,800 mg/day gabapentin
Number of subjects: 42
Study 36419530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 36419980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 351
Study 36419980 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 351
Study 36419980 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired executive cognitive function
Number of subjects: 351
Study 36420712 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (ATZ)
Number of subjects: 4400
Study 36420712 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 4400
Study 36421007 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 0
Study 36421007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 36421007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance -PCI (HA-PCI)
Number of subjects: 0
Study 36421007 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 0
Study 36421007 — intervention group
Group type: COMPARATOR
Intervention: HA-PCI
Number of subjects: 0
Study 36421007 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy added to chemotherapy
Number of subjects: 0
Study 36422666 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Radiography (DR) system
Number of subjects: 24
Study 36422666 — intervention group
Group type: COMPARATOR
Intervention: Computed Radiography (CR) system
Number of subjects: 24
Study 36422811 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of pre-operative imaging (CT scans in 55.77% of patients) during the COVID-19 pandemic
Number of subjects: 104
Study 36422811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no routine imaging)
Number of subjects: 104
Study 36422811 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of negative appendicectomy rates between groups
Number of subjects: 104
Study 36422852 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast cream 0.3% applied once daily for 14 days
Number of subjects: 26
Study 36422852 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast cream 0.3%
Number of subjects: 26
Study 36422983 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (aboBoNT-A)
Number of subjects: 49
Study 36423376 — intervention group
Group type: EXPERIMENTAL
Intervention: HDF assessment in HFpEF patients
Number of subjects: 68
Study 36423376 — intervention group
Group type: COMPARATOR
Intervention: Impaired systolic peak
Number of subjects: 68
Study 36423588 — intervention group
Group type: EXPERIMENTAL
Intervention: Danicopan (Factor D Inhibitor)
Number of subjects: 0
Study 36423588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36423805 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption during follow-up
Number of subjects: 650
Study 36423805 — intervention group
Group type: COMPARATOR
Intervention: No alcohol consumption
Number of subjects: 650
Study 36423925 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident non-COVID-19 ARI
Number of subjects: 2312
Study 36423925 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident COVID-19 (prior to omicron variant)
Number of subjects: 2312
Study 36423925 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident COVID-19 (post omicron variant)
Number of subjects: 2312
Study 36423968 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (PRU)
Number of subjects: 11714
Study 36424257 — intervention group
Group type: EXPERIMENTAL
Intervention: 4vHPV vaccine
Number of subjects: 65606
Study 36424257 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 65606
Study 36424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low muscle strength
Number of subjects: 64
Study 36424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 64
Study 36424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low muscle mass
Number of subjects: 64
Study 36424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cachexia
Number of subjects: 64
Study 36424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between low muscle mass and cachexia
Number of subjects: 64
Study 36424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between sarcopenia and cachexia
Number of subjects: 64
Study 36424360 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies targeting signaling pathways in CAFs
Number of subjects: 0
Study 36424612 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-aided rehabilitation devices (5 devices trialed for 30-45 minutes each)
Number of subjects: 7
Study 36424628 — intervention group
Group type: EXPERIMENTAL
Intervention: Conteltinib (CT-707) at doses of 50 to 800 mg QD
Number of subjects: 64
Study 36424756 — intervention group
Group type: EXPERIMENTAL
Intervention: TaqIA allele status
Number of subjects: 29
Study 36425296 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper arm transcutaneous oximetry
Number of subjects: 0
Study 36425296 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm transcutaneous oximetry
Number of subjects: 0
Study 36425320 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary SMICH patients
Number of subjects: 37
Study 36425320 — intervention group
Group type: COMPARATOR
Intervention: Single ICH patients
Number of subjects: 37
Study 36426287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (N)
Number of subjects: 31
Study 36426287 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab-Ipilimumab combination (NI)
Number of subjects: 31
Study 36426287 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 31
Study 36426287 — intervention group
Group type: COMPARATOR
Intervention: Overall study
Number of subjects: 31
Study 36426808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m2 weekly for 12 weeks followed by dose-dense epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) for four 2-week cycles
Number of subjects: 55
Study 36426808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel followed by dose-dense EC
Number of subjects: 55
Study 36427020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulixertinib 600 mg PO BID (de-escalated to 450 mg BID) plus gemcitabine and nab-paclitaxel (GnP)
Number of subjects: 18
Study 36427020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulixertinib plus GnP
Number of subjects: 18
Study 36427162 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab 10 mg administered daily during plasma exchange and for 30 days afterward, in combination with immunosuppressive treatment
Number of subjects: 21
Study 36427173 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel diagnostics (including WHO symptom screen, digital chest radiograph, sputum for Xpert MTB/Rif Ultra)
Number of subjects: 2100
Study 36427173 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for HIV, diabetes (HbA1c), chronic lung disease (spirometry), hypertension, and anaemia at baseline
Number of subjects: 2100
Study 36427173 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analyses including assessment of diagnostic accuracy
Number of subjects: 2100
Study 36427183 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with endocrine therapy (aromatase inhibitor or fulvestrant) as first-line treatment
Number of subjects: 0
Study 36427183 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with endocrine therapy
Number of subjects: 0
Study 36427183 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment effectiveness
Number of subjects: 0
Study 36427229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBO)
Number of subjects: 95
Study 36427229 — intervention group
Group type: COMPARATOR
Intervention: Standard care for NSTI (including surgery and broad-spectrum antibiotics)
Number of subjects: 95
Study 36427227 — intervention group
Group type: EXPERIMENTAL
Intervention: iCanChange (iCC) + modified Early Intervention Services (EIS)
Number of subjects: 100
Study 36427227 — intervention group
Group type: COMPARATOR
Intervention: Early Intervention Services (EIS)
Number of subjects: 100
Study 36427234 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) along with chemotherapy, supervised by a qualified kinesiologist, including endurance and resistance training at moderate intensity 3 times a week for 6 months.
Number of subjects: 186
Study 36427234 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) along with chemotherapy.
Number of subjects: 186
Study 36427234 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group).
Number of subjects: 186
Study 36427239 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation Makes the Move! intervention
Number of subjects: 89
Study 36427481 — intervention group
Group type: EXPERIMENTAL
Intervention: UNDERPIN-ICU multicomponent non-pharmacological nursing intervention program
Number of subjects: 30
Study 36427481 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitating factors identified in the application of the UNDERPIN-ICU program
Number of subjects: 30
Study 36427481 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindering factors identified in the application of the UNDERPIN-ICU program
Number of subjects: 30
Study 36427645 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes, delivering 6750 cGy to the prostate and 4500 cGy to the pelvic lymph nodes in 25 daily fractions.
Number of subjects: 54
Study 36427645 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes.
Number of subjects: 54
Study 36428084 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordantly graded aortic valve stenosis (DGAS) after adjustment for pressure recovery
Number of subjects: 1353
Study 36428100 — intervention group
Group type: EXPERIMENTAL
Intervention: SUMMIT study nodule management algorithm with a threshold volume of 200 mm
Number of subjects: 0
Study 36428272 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid consumption in patients with no opioid-related adverse effects
Number of subjects: 0
Study 36428272 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid consumption corresponding to one point on a cumulated opioid-related adverse event 0-10 scale
Number of subjects: 0
Study 36428272 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-related adverse effects for consecutive opioid dose intervals of 2 mg iv morphine equivalents
Number of subjects: 0
Study 36428744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ma-bTMB
Number of subjects: 0
Study 36428744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ma-bTMB
Number of subjects: 0
Study 36428784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative NLR <2.7
Number of subjects: 786
Study 36428784 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative NLR ≥2.7
Number of subjects: 786
Study 36429387 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 78
Study 36433685 — intervention group
Group type: EXPERIMENTAL
Intervention: SCB-2019 vaccine
Number of subjects: 154
Study 36433685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 36433753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast spindle band power fluctuations during NREM sleep
Number of subjects: 147
Study 36433753 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering level of fast spindles
Number of subjects: 147
Study 36433753 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean size of spindle clusters
Number of subjects: 147
Study 36433829 — intervention group
Group type: EXPERIMENTAL
Intervention: isatuximab 20 mg/kg QW/Q2W
Number of subjects: 28
Study 36433837 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning for PGY-1 residents
Number of subjects: 170
Study 36434329 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cryptogenic ischemic stroke
Number of subjects: 30
Study 36434329 — intervention group
Group type: COMPARATOR
Intervention: Stroke-free controls
Number of subjects: 30
Study 36434376 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 0
Study 36434376 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-calculated SQI
Number of subjects: 0
Study 36434392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hypofractionated stereotactic body radiation therapy with single-dose durvalumab (anti-PD-L1)
Number of subjects: 21
Study 36434554 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day) and Avelumab (800 mg on days 1 and 15)
Number of subjects: 50
Study 36434580 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier Wealthier Families (HWF) model
Number of subjects: 0
Study 36434580 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 36434602 — intervention group
Group type: EXPERIMENTAL
Intervention: LETSGO intervention (nurse-led consultations with eHealth technology)
Number of subjects: 0
Study 36434733 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Yeast Rice (RYR)
Number of subjects: 92
Study 36434733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 36434779 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 4018
Study 36434779 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 4018
Study 36435158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory transcutaneous carbon dioxide monitoring (tcCO2)
Number of subjects: 39
Study 36435158 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 39
Study 36435266 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY2586116 (160 μg) nasal spray
Number of subjects: 12
Study 36435266 — intervention group
Group type: COMPARATOR
Intervention: BAY2586116 (3 μg) nasal drops
Number of subjects: 12
Study 36435266 — intervention group
Group type: COMPARATOR
Intervention: BAY2586116 (30 μg) nasal drops
Number of subjects: 12
Study 36435266 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 12
Study 36435336 — intervention group
Group type: EXPERIMENTAL
Intervention: PyRadiomics
Number of subjects: 148
Study 36435336 — intervention group
Group type: EXPERIMENTAL
Intervention: SOPHiA Radiomics
Number of subjects: 148